Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $95.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented: "CRSP reported 3Q25 financial results including $132.9M OpEx, ending the quarter with ~$1.90B in cash. We were impressed by the progress in CRSP's in vivo programs, highlighted by detailed results from the Ph1 study of CTX310 presented in a late-breaking session at AHA with a concurrent NEJM publication (see our takeaways from this year's AHA). Additional preclinical updates on CTX340 were also intriguing, indicating a potential repeat-dosing strategy in future clinical studies. Also notably, new preclinical data for CTX460 for alpha-1 antitrypsin deficiency (AATD), presented at ESGCT, showcased CRSP's novel SyNTase editing technology, and we think the SyNTase platform holds broad opportunities and complements CRSP's existing approaches and in vivo programs. We update our model with actuals and maintain Outperform."

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $54.58 yesterday.

You May Also Be Interested In

• Berenberg Starts Saga Plc. (SGA:LN) at Buy
• Goldman Sachs Reiterates Conviction Buy Rating on TGS ASA (TGS:NO) (TGSNF)
• Goldman Sachs Upgrades Sampo Oyj (SAMPO:FH) (SAXPY) to Buy